Nicolas Mourier Email

SVP, CMC . Enzyvant

Current Roles

Employees:
27
Revenue:
$4.2M
About
About Enzyvant Enzyvant is a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases. Enzyvant's lead asset is the investigational tissue-based regenerative therapy, RVT-802, for congenital athymia, an ultra-rare and life-threatening pediatric immunodeficiency. RVT-802 has been granted multiple regulatory designations, including the US Food and Drug Administration expedited designation as a Regenerative Medicine Advanced Therapy (RMAT). Enzyvant is part of Sumitovant Biopharma (wholly owned by Sumitomo Dainippon Pharma), a global ecosystem of companies working on innovative research and development activities to transform healthcare and improve the lives of people worldwide. This global ecosystem has a geographic footprint spanning Japan, the US, China and the EU as well as talent, knowledge and resources across a wide spectrum of technologies and therapeutic areas.
Enzyvant Address
55 Cambridge Parkway
Cambridge, MA
United States
Enzyvant Email

Past Companies

EnzyvantSenior Vice President, Chemistry Manufacturing and Control
Anchiano TherapeuticsVice President, Head of Manufacturing
CSL ViforSenior Vice President of Manufacturing

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.